Last reviewed: June 25, 2026
Last updated: June 25, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Ozempic (semaglutide) doesn't have a strict minimum weight requirement—instead, prescribing doctors evaluate body mass index (BMI), weight-related health conditions, and individual risk factors. The FDA approved semaglutide for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related medical condition like type 2 diabetes, hypertension, or heart disease.
Understanding BMI Thresholds for Semaglutide Eligibility
Body mass index (BMI) is the primary metric physicians use to determine semaglutide candidacy, not absolute body weight. A BMI of 30 or higher qualifies as obesity; a BMI between 27 and 29.9 qualifies as overweight. If your BMI falls in the overweight range, you must have a documented weight-related condition to be eligible. These qualifying conditions include type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea.
Your actual weight in pounds or kilograms matters less than how that weight relates to your height and overall health profile. Two people weighing the same amount but with different heights will have different BMIs and potentially different eligibility status. PlexusDx physicians evaluate your complete health history during consultation to determine if compounded semaglutide injection—starting at $149/month—is appropriate for your situation.
Weight-Related Medical Conditions That Expand Eligibility
Having overweight status (BMI 27–29.9) combined with a weight-related disease significantly improves eligibility for semaglutide therapy. Type 2 diabetes, high blood pressure, and elevated cholesterol are the most common qualifying conditions. Cardiovascular disease, heart attacks, strokes, chronic kidney disease, and sleep apnea also count as weight-related conditions that lower the BMI threshold to 27. This means patients without obesity alone can still access treatment if they carry metabolic or cardiac risk.
The presence of these conditions reflects how excess weight damages multiple body systems over time. Semaglutide addresses the root cause—appetite and blood sugar regulation—which often improves or resolves these downstream health problems. During your initial PlexusDx consultation, your doctor will assess your full medical history to confirm eligibility and select the right formulation: compounded semaglutide injection or oral semaglutide.
How PlexusDx Personalizes Semaglutide Selection Based on Your Profile
PlexusDx doesn't just check a weight box—the medical team conducts a thorough evaluation of your metabolism, genetics, and health trajectory. The optional Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptides to identify your genetic predispositions for GLP-1 response, including variants in the GLP1R gene (rs6923761) and the GIPR gene (rs1800437). These insights help customize your protocol and dosing strategy from day one.
Once you qualify based on BMI and health factors, PlexusDx offers multiple semaglutide formats: compounded semaglutide injection starting at $149/month with your dose adjusted as needed while your price stays flat, or oral semaglutide at $249/month. No insurance is required, HSA and FSA accounts are accepted, and treatment is available in all 50 states. Your clinician will recommend the format and commitment tier that best fits your lifestyle and health goals.
Alternatives to Weight Minimums: Focus on Health Risk Instead
Modern weight management medicine shifts away from arbitrary weight cutoffs toward assessing overall cardiometabolic risk. A patient with a BMI of 27 and diabetes faces greater health urgency than a patient with a BMI of 32 but no comorbidities. This risk-based approach means your eligibility isn't determined by reaching a certain number on the scale—it's about protecting your heart, pancreas, joints, and longevity. PlexusDx physicians apply this framework during your free initial consultation.
If you've been declined for semaglutide elsewhere, PlexusDx may still find you eligible under a comprehensive clinical assessment. Factors like family history of diabetes, cardiovascular events, rapid weight gain, or metabolic syndrome patterns can strengthen your case even if your BMI sits below 30. Once approved, your cost is predictable—your dose may need to go up, but your price won't.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to weigh a certain amount to start Ozempic or compounded semaglutide?
No. Semaglutide eligibility is based on BMI thresholds and health conditions, not a specific weight number. If your BMI is 30+, you qualify. If your BMI is 27–29.9 and you have type 2 diabetes, high blood pressure, or other weight-related disease, you also qualify. PlexusDx evaluates your full profile to confirm eligibility.
What BMI do I need to be prescribed semaglutide?
A BMI of 30 or higher qualifies for semaglutide treatment. If your BMI is 27–29.9, you need at least one weight-related medical condition (diabetes, hypertension, heart disease, sleep apnea) to be eligible. PlexusDx physicians verify your BMI and health history during your initial consultation.
Can I get compounded semaglutide if I'm only slightly overweight?
Yes, if you have a documented weight-related condition. A person with BMI 28 and type 2 diabetes qualifies, even without obesity. PlexusDx compounded semaglutide injection starts at $149/month and is available in all 50 states without insurance.
Is there a maximum weight limit for semaglutide therapy?
No clinical maximum weight exists. Semaglutide works across the full spectrum of obesity, from mild to severe. Your dose is personalized to your metabolism and tolerance, not your starting weight. PlexusDx adjusts your dose as needed while maintaining flat monthly pricing.
How does the PlexusDx Precision Peptide Genetic Test help if I'm at the borderline of eligibility?
The Precision Peptide Genetic Test ($99 add-on after your first month) analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to predict your metabolic response and personalize treatment. If you're borderline based on weight alone, genetic insights into your peptide pathways may support clinical qualification and help optimize your therapy.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Soon Do You Start Losing Weight on Ozempic?
What Happens If You Eat Sweets While on Ozempic?